Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor

Tumor hypoxia is associated with therapy resistance and poor patient prognosis. Hypoxia-activated prodrugs, designed to selectively target hypoxic cells while sparing normal tissue, represent a promising treatment strategy. We report the pre-clinical efficacy of 1-methyl-2-nitroimidazole panobinosta...

Descripción completa

Detalles Bibliográficos
Autores principales: Skwarska, Anna, Calder, Ewen D.D., Sneddon, Deborah, Bolland, Hannah, Odyniec, Maria L., Mistry, Ishna N., Martin, Jennifer, Folkes, Lisa K., Conway, Stuart J., Hammond, Ester M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460716/
https://www.ncbi.nlm.nih.gov/pubmed/33910023
http://dx.doi.org/10.1016/j.chembiol.2021.04.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460716/
https://www.ncbi.nlm.nih.gov/pubmed/33910023
http://dx.doi.org/10.1016/j.chembiol.2021.04.004

Ejemplares similares